Can sofosbuvir and velpatasvir (Epclusa) tablets be taken for liver cancer?

Liver cancer patients should not use sofosbuvir and velpatasvir (Epclusa) combination to prolong life. The combination of sofosbuvir and velpatasvir only blocks the malignant transformation of hepatitis C patients to liver cancer, thereby reducing the damage to the liver caused by the hepatitis C virus. It has no therapeutic effect on patients with liver cancer. Sofosbuvir-velpatasvir combination is a newly developed antiviral drug that mainly has a certain clearance effect on hepatitis C virus. It is still only suitable for patients with hepatitis C. Liver cancer is not within the treatment scope of sofosbuvir-velpatasvir combination. Common adverse reactions of sofosbuvir and velpatasvir combination include headache, fatigue, rash, pharyngeal discomfort, nausea, and vomiting.